KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 3.54%.

  • Pacira BioSciences' EBIT Margin rose 863100.0% to 3.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.8%, marking a year-over-year increase of 151400.0%. This contributed to the annual value of 10.47% for FY2024, which is 234600.0% down from last year.
  • Latest data reveals that Pacira BioSciences reported EBIT Margin of 3.54% as of Q3 2025, which was up 863100.0% from 4.69% recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' EBIT Margin ranged from a high of 25.7% in Q2 2021 and a low of 82.77% during Q3 2024
  • In the last 5 years, Pacira BioSciences' EBIT Margin had a median value of 11.01% in 2022 and averaged 6.32%.
  • In the last 5 years, Pacira BioSciences' EBIT Margin crashed by -935800bps in 2024 and then soared by 863100bps in 2025.
  • Pacira BioSciences' EBIT Margin (Quarter) stood at 2.65% in 2021, then crashed by -317bps to 5.75% in 2022, then soared by 418bps to 18.3% in 2023, then fell by -28bps to 13.19% in 2024, then plummeted by -73bps to 3.54% in 2025.
  • Its EBIT Margin stands at 3.54% for Q3 2025, versus 4.69% for Q2 2025 and 1.18% for Q1 2025.